Clay B. Siegall

2017

In 2017, Clay B. Siegall earned a total compensation of $8.6M as President and CEO at Seattle Genetics, a 10% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$934,500
Option Awards$3,217,921
Salary$887,146
Stock Awards$3,561,064
Other$15,713
Total$8,616,344

Siegall received $3.6M in stock awards, accounting for 41% of the total pay in 2017.

Siegall also received $934.5K in non-equity incentive plan, $3.2M in option awards, $887.1K in salary and $15.7K in other compensation.

Rankings

In 2017, Clay B. Siegall's compensation ranked 834th out of 14,666 executives tracked by ExecPay. In other words, Siegall earned more than 94.3% of executives.

ClassificationRankingPercentile
All
834
out of 14,666
94th
Division
Manufacturing
281
out of 5,770
95th
Major group
Chemicals And Allied Products
71
out of 2,074
97th
Industry group
Drugs
51
out of 1,730
97th
Industry
Biological Products, Except Diagnostic Substances
9
out of 316
97th
Source: SEC filing on April 3, 2018.

Siegall's colleagues

We found seven more compensation records of executives who worked with Clay B. Siegall at Seattle Genetics in 2017.

2017

Eric Dobmeier

Seattle Genetics

Chief Operating Officer

2017

Jonathan Drachman

Seattle Genetics

Chief Medical Officer

2017

Todd Simpson

Seattle Genetics

Chief Financial Officer

2017

Vaughn Himes

Seattle Genetics

Chief Technical Officer

2017

Jean Liu

Seattle Genetics

General Counsel

2017

Jean Liu

Seattle Genetics

General Counsel

2017

Darren Cline

Seattle Genetics

Former Executive Vice President, Commercial

News

You may also like